Sign up to access historical data
Similar companies
| Company | Est. Transaction Value | |
|---|---|---|
 |
Gilead SciencesGILD |
-$33,000 |
 |
AmgenAMGN |
$130,000 |
 |
Editas MedicineEDIT |
-$8,000 |
 |
Alnylam PharmaceuticalsALNY |
-$8,000 |
 |
United TherapeuticsUTHR |
-$210,000 |
Trades by US Politicians
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna | Nov 15, 2024 | Buy | $1K - $15K |
| Rohit Khanna Democrat | May 29, 2024 | Sell | $1K - $15K |
| Rohit Khanna Democrat | Apr 26, 2024 | Buy | $1K - $15K |
| Rohit Khanna Democrat | May 23, 2023 | Sell | $1K - $15K |
| Rohit Khanna Democrat | May 19, 2023 | Sell | $1K - $15K |
| Rohit Khanna Democrat | Apr 25, 2023 | Buy | $1K - $15K |
Who is the latest politician to buy or sell Catalent shares?
Ro Khanna purchased Catalent shares most recently on November 15, 2024.
Which politician has bought the most CTLT stock in the last two years?
Rohit Khanna has bought the most CTLT stock in the last 2 years, with an estimated value of $16,000.
Which politician has sold the most CTLT stock over the last two years?
Rohit Khanna has sold the most CTLT stock in the last 2 years, with an estimated value of $24,000.
What is the total value of politicians trading CTLT stock in the last 2 years?
There have been no US politicians buying or selling Catalent in the last 2 years.
How do insider transactions over the last 2 years reflect on Catalent's market confidence?
Over the last 2 years, insider transactions for Catalent have been balanced between buying and selling, showing a neutral stance among insiders towards the company's market performance. This trend of more purchases than sales could be a positive signal to potential investors about the politicians view on the company's future and growth potential.
Why should individual investors pay attention to the stock transactions of US politicians?
Monitoring US politicians' stock trades is valuable because they may have inside information about upcoming policies that could affect stock values, providing investors with valuable clues for making informed decisions.
